Literature DB >> 511357

Dose dependence in human absorption of aminopenicillins.

J Sjövall.   

Abstract

The concentration of antibiotic in a focus of infection depends both on the peak serum concentration and on the area under the serum concentration time curve (AUC). A knowledge of the relationship between increased doses and the corresponding response in serum concentration would be relevant as a basis for determining an adequate clinical dosage. Dose-related changes in the two pharmacokinetic variables, peak serum concentration and AUC, after single doses of bacampicillin are compared with data on different aminopenicillins from other studies. With ampicillin there is a nonlinear relationship between both dose-peak and dose-AUC. The results indicate that the poor absorption of oral ampicillin can only be partially compensated for by increasing the oral dose. But with amoxycillin and the ampicillin esters the absorbed amount (AUC) is a linear function of the dose in the dosage range investigated. The increase in peak serum level with high doses of oral ampicillin is far less than proportional, while this tendency was less pronounced for amoxycillin and still less for pivampicillin, talampicillin and bacampicillin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 511357     DOI: 10.1007/bf01659771

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  14 in total

1.  Absorption and excretion of "Penbritin".

Authors:  E T KNUDSEN; G N ROLINSON; S STEVENS
Journal:  Br Med J       Date:  1961-07-22

2.  Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.

Authors:  P G Welling; H Huang; P A Koch; W A Craig; P O Madsen
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

3.  Penetration of antibiotics into fibrin loci in vivo. 3. Intermittent vs. continuous infusion and the effect of probenecid.

Authors:  M Barza; J Brusch; M G Bergeron; L Weinstein
Journal:  J Infect Dis       Date:  1974-01       Impact factor: 5.226

4.  Continuous versus intermittent intravenous antibiotics.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1968-07-26       Impact factor: 1.909

5.  Bacampicillin: a new orally well-absorbed derivative of ampicillin.

Authors:  N O Bodin; B Ekström; U Forsgren; L P Jalar; L Magni; C H Ramsay; B Sjöberg
Journal:  Antimicrob Agents Chemother       Date:  1975-11       Impact factor: 5.191

6.  Pharmacological and clinical study of bacampicillin in acute peritonsillitis--a comparison with ampicillin.

Authors:  H O Hallander; A Flodström; J Sjövall
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

7.  Cefazolin and cephradine: relationship between serum concentrations and tissue contents in mice.

Authors:  M W Kunst; H Mattie
Journal:  Infection       Date:  1978       Impact factor: 3.553

8.  Bioavailability and metabolism of talampicillin.

Authors:  K H Jones; P F Langley; L J Lees
Journal:  Chemotherapy       Date:  1978       Impact factor: 2.544

9.  Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration.

Authors:  D A Spyker; R J Rugloski; R L Vann; W M O'Brien
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

10.  Comparative clinical pharmacology of bacampicillin and high oral doses of ampicillin.

Authors:  L Magni; J Sjövall; E Syvälahti
Journal:  Infection       Date:  1978       Impact factor: 3.553

View more
  4 in total

1.  Pharmacokinetics of a new oral formulation of amoxicillin.

Authors:  M H Prevot; F Jehl; B Rouveix
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jan-Mar       Impact factor: 2.569

Review 2.  Studies on aminopenicillin developments. Proceedings of a symposium. Concluding remarks.

Authors:  T Bergan
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 3.  The aminopenicillins: development and comparative properties.

Authors:  D S Reeves; D W Bullock
Journal:  Infection       Date:  1979       Impact factor: 3.553

4.  Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses.

Authors:  T Bergan; S B Thorsteinsson; I M Kolstad; S Johnsen
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.